World Hemophilia Day: Kedrion’s commitment
Apr 13, 2022 |
CORPORATE
Guaranteeing equitable access to treatment is the central theme of the 2022 edition
Kedrion-Pharmacosmos partnership for the treatment of Anemia in Italy
Mar 02, 2022 |
CORPORATE
Exclusive agreement signed for the distribution of a novel iron-based therapy
Results of the “Words in Hemophilia: Towards Patient Engagement” study have been published
Feb 10, 2022 |
CORPORATE
The project supported by Kedrion defines some of the key principles intended to improve patient envolvement
Kedrion and LFB sign industrial cooperation agreement
Jan 31, 2022 |
CORPORATE
Scope is supplying Immunoglobulins to meet patient demand in France
Kedrion grows in North America as it completes acquisition of Prometic
Oct 18, 2021 |
CORPORATE
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency
KIDCARES10, First Patient Treated in Pediatric PI Study
Jul 26, 2021 |
CORPORATE
Thirty patients aged 2 to 17yo to be enrolled over five European countries
Kedrion stronger in North America and further committed to rare diseases
Jun 25, 2021 |
CORPORATE
Agreement with Canadian-based Liminal BioSciences signed on June 22nd
Kedrion supports young doctors: the Epateam Young Academy gets underway
May 11, 2021 |
CORPORATE
The initiative aims to promote the training of new generations of clinicians in the field of liver transplantation